NEURIZON Aktie

>NEURIZON Performance

1 Woche: +7,9%

1 Monat: -15,5%

3 Monate: -6,8%

6 Monate: -34,9%

1 Jahr: -36,9%

laufendes Jahr: -6,8%

>NEURIZON Aktie

Name:

NEURIZON THERAPEUTICS

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU0000357261 / A40STF

Symbol/ Ticker:

ECQ0 (Frankfurt)

Kürzel:

FRA:ECQ0, ETR:ECQ0, ECQ0:GR

Index:

Webseite:

https://www.neurizon.com/

Profil:

Neurizon Therapeutics Ltd is a clinical-stage biotechnology company specializing in the development of therapeutics for neurodegenerative diseases. Founded in 2000 and headquartered in Melbourne, Australia, the company focuses on innovative drug disc..
>Volltext..

Marktkapitalisierung:

33.07 Mio. EUR

Unternehmenswert:

29.47 Mio. EUR

Umsatz:

EBITDA:

-12.05 Mio. EUR

Nettogewinn:

-8.58 Mio. EUR

Gewinn je Aktie:

-0.02 EUR

Schulden:

0.94 Mio. EUR

Liquide Mittel:

4.58 Mio. EUR

Operativer Cashflow:

-10.09 Mio. EUR

Bargeldquote:

1.13

Umsatzwachstum:

Gewinnwachstum:

3.15%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NEURIZON

Letzte Datenerhebung:

05.04.26

>NEURIZON Kennzahlen

Aktien/ Unternehmen:

Aktien: 708.13 Mio. St.

Frei handelbar: 93.12%

Leerverk. Aktien: -

Rückkaufquote: -18.84%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 333.83%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 4.33

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -96.23%

Eigenkaprendite: -147.09%

>NEURIZON Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin

>NEURIZON Chart & Kurs - Stuttgart

>NEURIZON News

26.02.26 - 21:36	Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial (PR Newswire)
	Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3......

26.02.26 - 02:00	Neurizon doses first patient with NUZ-001 in amyotrophic lateral sclerosis trial (Market Herald)
	Neurizon Therapeutics (ASX:NUZ) has dosed its first patient in the company's amyotrophic…...

23.12.25 - 09:01	XFRA: ECQ0: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN NEURIZON THERAPEUTICS ECQ0 AU0000357261 AB/FROM ONWARDS 23.12.2025 08:20 CET...

23.12.25 - 02:12	Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial (Small Caps)
	Neurizon Therapeutics (ASX: NUZ) has successfully raised over $44 million AUD through a multi-pronged capital raise, securing funding to advance its lead drug candidate NUZ-001 through the **H...

19.12.25 - 08:54	XFRA: ECQ0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL NEURIZON THERAPEUTICS ECQ0 AU0000357261 BAW/UFN...

19.12.25 - 08:01	XFRA: INSTRUMENT_SUSPENSION - AU0000357261 (XETRA)
	Instrument ID [21314063] (ECQ0 - AU0000357261) suspended...

11.12.25 - 22:06	FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial (PR Newswire)
	Highlights: FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single IRB approval, site initiations and......

11.12.25 - 21:54	FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial (PR Newswire)
	Highlights: FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single IRB approval, site initiations and......

27.11.25 - 00:36	Elanco executive appointed as Neurizon′s Board Observer (PR Newswire)
	MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the......

06.10.25 - 03:00	Neurizon Terapeutics climbs +7% after FDA lifts clinical hold on NUZ-001 (Market Herald)
	Neurizon Therapeutics (ASX:NUZ) has opened Monday up +7% after the U.S. Food…...

18.09.25 - 08:09	XFRA: ECQ0: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN NEURIZON THERAPEUTICS ECQ0 AU0000357261 AB/FROM ONWARDS 18.09.2025...

16.09.25 - 08:25	XFRA: ECQ0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL NEURIZON THERAPEUTICS ECQ0 AU0000357261 BAW/UFN...

16.09.25 - 08:01	XFRA: INSTRUMENT_SUSPENSION - AU0000357261 (XETRA)
	Instrument ID [21314063] (ECQ0 - AU0000357261) suspended...

21.08.25 - 07:01	Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals (Market Herald)
	In the latest Watchlist interview, HotCopper sat down with Neurizon Therapeutics (ASX:NUZ)…...

30.07.25 - 05:01	Neurizon inks $1.5M loan against R&D Tax Rebate (Market Herald)
	Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a…...

28.07.25 - 11:12

XFRA: SPAFR - HANDELSUNTERBRECHUNG IN DIVERSEN AUSLANDSAKTIEN - TEIL 1 (XETRA)

CA59142H1073 SE0002480442 NZARRE0004S7 AU000000DRO2 NO0011202772 AU0000157679 AU0000367443 CA92905D2032 CA53000A1066 CA21037X1006 CA70337R1073 CA00248Y1079 CA8970021017 AT0000969985 AU0000297962 AU000000DMP0 NZXROE0001S2 SE0001852419 GB00BZ3CNK81 US55302T2042 AU0000241416 CA92865M1023 CA33833X1015 CA50077N1024 AU0000397705 AU000000WBT5 CA22674C1023 JP3128800004 CA56089A4000 CA05455R2081 CA90366H4089 CH0126639464 AU0000035701 CA92847V5018 AU0000221251 NO0010872468 CA46500E8678 AU000000PLS0 AU000000SYR9 AU000000JHX1 NL0000289783 JP3853000002 CA8277191059 CA42249X1006 GB00BKWQ1135 CA7807641062 BMG709641044 CA40066W1068 NL0015000LU4 BMG0403V2062 CA8716261075 FI0009005870 JP3862400003 CA36249G1090 AU000000BRN8 SG2G55000001 CA77273P2017 GB00BJP0B151 NZCNUE0001S2 CH0010675863 AU0000138190 CA8985301008 US25460P2039 CA95556L1013 JP3829750003 CA9638101068 AU000000AKM7 CA74841L1013 GG00B28C2R28 AU000000BRG2 AU0000357261 GB00BNGY4Y86 CA64046G1063...

10.07.25 - 06:01	Thursday’s HotCopper trends: Mystery Trigg halt, Neurizon FDA feedback \| July 10 (Market Herald)
	Trigg Minerals (ASX:TMG) has drawn the most attention on the HotCopper forums…...

04.07.25 - 02:01	Neurizon significantly advances NUZ-001, enters global licensing agreement (Market Herald)
	Neurizon Therapeutics (ASX:NUZ) has this week arrived at its next “watershed moment”…...

03.07.25 - 13:42	Elanco in licensing pact with Australia’s Neurizon (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.07.25 - 01:36	Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001 (PR Newswire)
	Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram